The fundraising landscape for healthcare and life science companies has changed dramatically over the past several years. Entrepreneurs and business owners in these industries need to look toward emerging categories of investors to provide the funding that was historically serviced by venture capital firms (VC’s). Corporate venture funds, angels and angel networks, government agencies, and foundations are all actively investing in these sectors and represent newer, non-traditional avenues for raising capital. However, the latest growing trend is the participation of family offices.(more…)
"Working with life science companies is not like serving other industries. There are myriad legal and financial eccentricities - accounting for multiple financing sources makes accounting especially complex, for instances and protecting intellectual property is key. Early-stage companies may need their hand held as they focus on the science and outsource everything else." San Diego Business Journal
When owners decided consider to sell their company, one of the first things they consider is building a list of high-fit potential acquirers for the business. With private equity (financial) acquirers becoming so abundant in the last 10 years (over 2,500 in North America), the list of potential acquirers to approach in the M&A sale process is likely to consist of both strategic acquirers and financial acquirers.
We are excited to announce the addition of experienced finance professional, Matt Ramirez, to the firm. Matt brings with him a great depth of finance experience having served previously as a Senior Associate with Ernst & Young's Assurance Services Practice where he led teams in the execution of public and private company financial statement audits.(more…)
Los Angeles, CA April 24, 2018 — Objective Capital Partners, a leading middle market investment banking firm, is pleased to announce that it served as the exclusive financial advisor to StudyKIK LLC, a rapidly-growing healthcare IT company, on its acquisition by Kinderhook Industries LLC.
“Matt and his team have done a remarkable job in creating a leading patient recruiting platform which is having an enormous impact by making it dramatically more efficient for clinical trial companies to find and engage the high-fit trial volunteers they need to bring new and innovative treatments to market,” said Channing Hamlet, Managing Director of Objective Capital Partners. “We are privileged to have had this opportunity to help StudyKIK and couldn’t be more excited about the future of the company.”(more…)
You received an inquiry or offer to buy your company - now what?
An unsolicited acquisition offer for your business can come as a surprise. If you haven’t considered selling your company or you are 3-5 years out from your planned exit, you may be caught off guard. This can lead to stress and worry about making the right decision in order maximize the sales price.
No matter what your industry of focus is, there are some key strategies you should employ when faced with an inquiry or offer to acquire your company. The decision you make must be an informed decision in alignment with your objectives.(more…)
From the moment you make a decision to set up and operate a business, you’re in the “business lifecycle.” Fasten your seatbelt before the drive as you’ll journey from idea to startup, and if successful, through to the growth and maturity phases. Each stage of the lifecycle has a unique set of obstacles to deal with and overcome. Being flexible in your thinking and adapting your strategy as you move along will serve you well. This not only applies to a business strategy but also to the financial plans to support the development and growth of the Company. A capital financing strategy should summarize investor targets for outreach by stage of the lifecycle, inflection points and how these will change valuation, and the actions to be taken over a three-to-five year period to achieve the company's goals in its business evolution. Putting together the strategy is hard work that takes time and considerable thought. Raising money is also hard work, so get started today.(more…)
David H. Crean, PhD, Managing Director and head of our Life Sciences and Healthcare Practice Group provides his thoughts and guidance to entrepreneurs, founders and business owners in the life sciences sector on what he has seen as successful pitches to investors and strategic companies in the initial pitches of their company and technology. By providing as much of the information noted below during the process, we believe that you can improve the probability and chances of landing a transaction that supports company growth or exit strategies. David has also previously authored related articles on this topic that can be viewed here and here. Happy to clarify any topic if needed.(more…)
San Diego, CA and Flagstaff, AZ, April 12, 2018: — Symple Surgical, Inc., a privately-held, early-stage medical device company focused on developing novel therapeutic technologies using microwave technology for treatment of life-threatening chronic conditions, is pleased to the announce that they have retained Objective Capital Partners as their exclusive financial advisor. Objective Capital Partners, a middle-market Investment Banking firm located in Southern California and focused on mergers & acquisitions (M&A), strategic advisory, capital financing and valuation services, will seek to identify strategic partnerships and financial investors for the Company to progress their lead product Grizzly™ targeting pre-cancerous cells in the elimination of Barrett's Esophagus and Esophageal Adenocarcinoma, the fastest growing cancer worldwide.
Barrett’s Esophagus (BE) is a premalignant condition caused by stomach acid or gastrointestinal reflux disease (GERD) mutating healthy cells in the lower esophagus into Barrett’s cells. Approximately 90% of Esophageal Adenocarcinoma (EAC) patients do not receive a prior diagnosis of Barrett’s Esophagus (BE). BE affect’s more than 12 million American adults, and is associated with a 30-fold increased risk of developing EAC. This new treatment will provide an alternative to the Radiofrequency Ablation Technology (“RFA”) and cryoablation technologies currently in use for treatment of BE thereby reducing the number of episodes of treatment and providing unparalleled user control for adequate cell removal.(more…)
San Diego, April 9, 2018 — Objective Capital Partners is pleased to announce the promotion of Michael Kim to Managing Director. Michael contributes over 15 years of mergers & acquisitions (M&A) and corporate finance experience across numerous industries including technology, consumer, and business services. He was also recognized in 2016 by M&A Advisor as a M&A Advisor Emerging Leaders Award Winner.
Mr Kim joined Objective Capital in 2015 and has been responsible for all aspects of transaction lifecycle including client sourcing, due diligence, negotiation, valuation analyses, and transaction closings. In his new role, Michael will continue serving the firm’s clients in the areas of transaction origination, analysis and execution.(more…)
This article is provided for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.